{
  "image_filename": "figure_p4_mrg_det_3_001.png",
  "image_path": "Arunachalam_et_al.__2021_/extracted/figures/figure_p4_mrg_det_3_001.png",
  "image_type": "Figure",
  "page_number": 4,
  "block_id": "mrg_det_3_001",
  "claim_id": "claim_005",
  "claim": "Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
  "supports_claim": false,
  "explanation": "Scientific illustration comparing structural features of native influenza HA protein (HA1/HA2 heterodimer with complex-type sialylated N-linked glycans and cleaved fusion peptide) and recombinant HA produced in insect cells (single precursor HA0 with paucimannose glycans and uncleaved fusion peptide) The figure does not support the claim because it only shows structural glycoprotein features of HA and does not mention Flublok, Fluarix, or any clinical trial comparisons, and thus does not support the claim Note: No trial or vaccine names are visible; the content is focused on protein structure rather than clinical evaluation",
  "model_used": "o4-mini",
  "detailed_analysis": {
    "supports_claim": false,
    "image_description": "Scientific illustration comparing structural features of native influenza HA protein (HA1/HA2 heterodimer with complex-type sialylated N-linked glycans and cleaved fusion peptide) and recombinant HA produced in insect cells (single precursor HA0 with paucimannose glycans and uncleaved fusion peptide)",
    "evidence_found": null,
    "reasoning": "The figure does not support the claim because it only shows structural glycoprotein features of HA and does not mention Flublok, Fluarix, or any clinical trial comparisons, and thus does not support the claim",
    "confidence_notes": "No trial or vaccine names are visible; the content is focused on protein structure rather than clinical evaluation"
  }
}